Aberdeen Group’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
Other funds holding NKTR
Aberdeen Group's NKTR Position: Q4 2022 in Review
Aberdeen Group sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 750 shares — an estimated $36K sold.
Aberdeen Group first reported a position in NKTR in Q3 2017 and held it in 21 quarters. The position peaked at $9.88M in Q3 2018. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.
- Aberdeen Group reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
- Aberdeen Group sold 750 Nektar Therapeutics shares in Q4 2022, an estimated $36K.
- Aberdeen Group first reported a position in Nektar Therapeutics in Q3 2017 and held it in 21 quarters.
- Aberdeen Group's Nektar Therapeutics position peaked at $9.88M in Q3 2018.
- 214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.
Based on Aberdeen Group's 13F filing for Q4 2022, filed 10 Feb 2023.